-+ 0.00%
-+ 0.00%
-+ 0.00%

CANDEL THERAPEUTICS INC: EXPECT PHASE 2 NSCLC LONG-TERM SURVIVOR DATA IN Q1 2026 AND PHASE 3 INITIATION IN Q2 2026

Reuters·11/13/2025 13:23:54

Please log in to view news